<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01784978</url>
  </required_header>
  <id_info>
    <org_study_id>SUNRISES STUDY (CRAD001LIC34T)</org_study_id>
    <nct_id>NCT01784978</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer</brief_title>
  <acronym>SUNRISES</acronym>
  <official_title>Randomized ph. II Study to Explore Efficacy and Feasibility of Upfront Rotations Between SUNitinib and Everolimus vs Sequential Treatment of 1st lIne Sunitinib &amp; 2nd Line EverolimuS Until Progression in Pats Met. Clear Cell Renal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associació per a la Recerca Oncologica, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pivotal S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Associació per a la Recerca Oncologica, Spain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the progression-free survival, of patients who&#xD;
      receive rotations of sunitinib and everolimus versus patients who receive sunitinib as a&#xD;
      first line treatment followed by everolimus when progression occurs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized phase II study to investigate the feasibility of&#xD;
      alternating cycles of treatment with sunitinib and everolimus compared to sequential&#xD;
      treatment of sunitinib followed by everolimus.&#xD;
&#xD;
      The study population consists of adult patients (over 18 years old) with clear cell mRCC&#xD;
      (Metastatic Renal Cell Cancer) who have not received prior therapy for their metastatic&#xD;
      disease.&#xD;
&#xD;
      The purpose of the study is to determine the progression free survival, feasibility and&#xD;
      safety profile of the experimental arm compared to standard of care.&#xD;
&#xD;
      In the experimental arm alternating treatment will consist of repeating cycles of 24 weeks of&#xD;
      treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12&#xD;
      weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear&#xD;
      cell renal cancer. The comparative arm will be the standard regimen of sunitinib (50 mg pd&#xD;
      4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1)&#xD;
      until progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">February 12, 2013</start_date>
  <completion_date type="Actual">May 8, 2017</completion_date>
  <primary_completion_date type="Actual">May 8, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) rate 1 year</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS of rotational arm versus PFS of the 2 lines in control arm</measure>
    <time_frame>From date of randomization until the date of first documented progression assesed up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of the tratment start to the date of death or the last contact for alived patients at the momment of data censored. Assesed up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile</measure>
    <time_frame>From the first treatment dose until 28 days after study treatment discontinuation. Assesed up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate per arm</measure>
    <time_frame>From the date of first tumor response to the date of progression or start date of other cancer therapy. Assesed up to 30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Rotational arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating cycles of treatment with sunitinib and everolimus; repeating cycles of 24 weeks of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear cell renal cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparative arm will be the standard regimen of sunitinib (50 mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1) until progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50 mg pd</description>
    <arm_group_label>Rotational arm</arm_group_label>
    <arm_group_label>Sequential arm</arm_group_label>
    <other_name>SUTENT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>10 mg pd</description>
    <arm_group_label>Rotational arm</arm_group_label>
    <arm_group_label>Sequential arm</arm_group_label>
    <other_name>AFINITOR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Renal cell carcinoma with a predominant clear cell component confirmed by histology.&#xD;
&#xD;
          -  Advanced disease: metastatic AND, not suitable for resection&#xD;
&#xD;
          -  Male or female, aged 18 years or older&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0 or 1&#xD;
&#xD;
          -  Low or intermediate MSKCC (Memorial Sloan Kettering Cancer Center) prognostic risk&#xD;
             score,i.e. no more than 2 of the following:&#xD;
&#xD;
               -  Karnofsky performance status (&lt;80%)&#xD;
&#xD;
               -  Low serum hemoglobin (≤ 13 g/dL for males and ≤ 11.5 g/dL for females)&#xD;
&#xD;
               -  High corrected serum calcium (≥ 10 mg/dL)&#xD;
&#xD;
          -  Target and/or non-target lesions according to RECIST 1.1 ( Response Evaluation&#xD;
             Criteria in Solid Tumors)&#xD;
&#xD;
          -  Expected survival of at least 3 months.&#xD;
&#xD;
          -  No prior systemic treatment. But adjuvant treatment is ok if stopped from ≥ 24 months&#xD;
&#xD;
          -  Adequate bone marrow function as shown by:&#xD;
&#xD;
          -  Adequate liver function as shown by:&#xD;
&#xD;
          -  Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN (upper limit of&#xD;
             normal)&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥55% on gated cardiac blood pool scan, or normal&#xD;
             left ventricular function and fractional shortening on echocardiogram (according to&#xD;
             institutional limits).&#xD;
&#xD;
          -  SBP (systolic blood pressure) ≤140mmHg and DBP (diastolic blood pressure)&#xD;
&#xD;
               -  90mmHg (it is acceptable to initiate antihypertensive treatment prior to&#xD;
                  registration to achieve these goals).&#xD;
&#xD;
          -  Able to commence treatment within 7 days of registration.&#xD;
&#xD;
          -  Willing and able to comply with follow-up and all other protocol requirements.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with VEGF-targeting agents or multi-kinase inhibitors or&#xD;
             mTOR-targeting agents&#xD;
&#xD;
          -  Active central nervous system metastases.&#xD;
&#xD;
          -  Other malignancy diagnosed within the last 5 years, except the following if adequately&#xD;
             treated: superficial squamous cell carcinoma or basal cell carcinoma of skin,&#xD;
             superficial bladder cancer (T1 and G1 or T1 and G2), stage 1 cervical cancer.&#xD;
&#xD;
          -  Treatment with an investigational agent in the last 4 w.&#xD;
&#xD;
          -  Known to be HIV positive.&#xD;
&#xD;
          -  Evidence of chronic hepatitis due to hepatitis B virus (HBV) or hepatitis C virus&#xD;
             (HCV)&#xD;
&#xD;
          -  Clinically significant heart disease (NYHA Class III or IV)&#xD;
&#xD;
          -  History of hypertension requiring hospitalization.&#xD;
&#xD;
          -  Other serious illnesses,&#xD;
&#xD;
          -  Immunotherapy or chemotherapy in the last 4 w (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  Major surgery in the last 4 w, or planned in the next 6 w&#xD;
&#xD;
          -  Radiation therapy in the last 2 w, or planned in the next 6 w&#xD;
&#xD;
          -  NCI CTCAE (Common Toxicity Criteria for Adverse Effects) version 4.0 grade 3 or worse&#xD;
             hemorrhage in last 4 w.&#xD;
&#xD;
          -  Any of the following in the last year: myocardial infarction, severe/unstable angina,&#xD;
             coronary/peripheral artery bypass graft, symptomatic congestive heart failure,&#xD;
             cerebrovascular accident or transient ischemic attack, or pulmonary embolism.&#xD;
&#xD;
          -  Pre-existing thyroid abnormality with thyroid function that cannot be maintained in&#xD;
             the normal range with medication.&#xD;
&#xD;
          -  Ongoing cardiac dysrhythmias of NCI CTCAE version 4.0 grade ≥2, atrial fibrillation of&#xD;
             any grade, or prolongation of the corrected QT interval (QTc) to &gt;450 msec for males&#xD;
             or &gt;470 msec for females&#xD;
&#xD;
          -  Uncontrolled diabetes as defined by fasting serum glucose &gt;1.5 X ULN.&#xD;
&#xD;
          -  Pregnancy,lactation. Inadequate contraception.&#xD;
&#xD;
          -  Known allergy or hypersensitivity to everolimus, sunitinib or iodine.&#xD;
&#xD;
          -  Medical or psychiatric condition that compromises the patient's ability to give&#xD;
             informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquim Bellmunt, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associacio Per la Recerca Oncológica (APRO)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Bordeaux University</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALEXANDRA General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clara Campal. Hospital Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Greece</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>December 11, 2012</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2013</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>renal</keyword>
  <keyword>metastatic</keyword>
  <keyword>clear</keyword>
  <keyword>cell</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Alternating</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

